Ahnak/Desmoyokin Is Dispensable for Proliferation, Differentiation, and Maintenance of Integrity in Mouse Epidermis  by Kouno, Michiyoshi et al.
See related Commentary on page xiv
Ahnak/Desmoyokin Is Dispensable for Proliferation, Differentiation,
and Maintenance of Integrity in Mouse Epidermis
Michiyoshi Kouno,w Gen Kondoh, Kyoji Horie,z Nobuyasu Komazawa, Norito Ishii,w Yoshie Takahashi,w
Junji Takeda,z and Takashi Hashimotow
Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan; wDepartment of Dermatology, Kurume
University School of Medicine, Fukuoka, Japan; zCollaborative Research Center for Advanced Science and Technology, Osaka University, Osaka, Japan
Desmoyokin was ﬁrst isolated from bovine muzzle epidermis and thought to be an epidermal desmosome-related
protein. We previously demonstrated that the Desmoyokin gene is identical to the Ahnak gene, which is expres-
sed ubiquitously and downregulated in neuroblastomas. It was assumed Ahnak/Desmoyokin was associated with
epidermal cell adhesion, tumorigenesis, cell proliferation and differentiation, and embryonic development. To
determine the precise biological function of Ahnak/Desmoyokin, we generated a null mutation in ES cells and mice.
The resultant Ahnak/Desmoyokin-deﬁcient ES cells normally differentiated into embryoid bodies and neural cells.
The mutant mice were viable and fertile and showed no gross developmental defects. Electron microscopic ex-
amination of skin sections demonstrated that the ultrastructure of epidermal intercellular junctions, including
desmosomes, of the mutant mice was indistinguishable from that of wild-type mice. Two-stage chemical skin
carcinogenesis experiments showed no difference in frequency or onset of cutaneous tumor formation between
wild-type and mutant mice. Moreover, no tumorigenesis was observed in other tissues and organs of mutant mice
up to 2 y of age. These results lead us to conclude that Ahnak/Desmoyokin deﬁciency has only a minimal effect on
epidermal cell adhesion, tumorigenesis, cell proliferation and differentiation, and overall mouse development.
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Ahnak/Desmoyokin is a phosphoprotein of exceptionally
large size (700 kDa) and is encoded by an intronless gene
located on human chromosome 11q12–13 (Shtivelman et al,
1992; Shtivelman and Bishop, 1993). The Ahnak/Desmoyo-
kin protein consists of three structural domains: a short NH2
terminus of 251 amino acids, a large central domain of 4392
amino acids composed of highly conserved repeated ele-
ments, and a unique COOH terminus of 1000 amino acids.
The latter contains putative regulatory elements including
nuclear export and localization signals, as well as phos-
phorylation sites for protein kinase B and C (PKB and PKC)
(Hashimoto et al, 1995; Nie et al, 2000; Sussman et al,
2001). Although its precise biological function remains un-
known, various experimental studies have suggested sev-
eral possible roles for Ahnak/Desmoyokin (Haase et al,
1999; Sekiya et al, 1999; Gentil et al, 2001; Downs et al,
2002; Benaud et al, 2004).
Expression and phosphorylation of Ahnak/Desmoyokin
are regulated in a cell-cycle-dependent manner. The highest
expression is observed in quiescent or differentiating cells
and total phosphorylation is enhanced in proliferating cells
(Shtivelman and Bishop, 1993). Downregulation of Ahnak/
Desmoyokin in neuroblastoma cells, small cell lung carci-
nomas, and Burkitt lymphomas (Shtivelman et al, 1992), as
well as in HRAS-transformed tumorigenic rat embryo fibro-
blasts (Zuber et al, 2000), suggests the involvement of
Ahnak/Desmoyokin in tumor formation. Ahnak/Desmoyokin
binds and activates phospholipase C-g 1 in the presence of
arachidonic acid (Sekiya et al, 1999). In cardiomyocytes,
Ahnak/Desmoyokin is associated with the regulatory b2
subunit of L-type calcium channels (Haase et al, 1999; Ho-
haus et al, 2002), suggesting its potential implication in the
regulation of channel activity. Ahnak/Desmoyokin also binds
the EF-hand calcium-binding protein S100B in a strictly
calcium-dependent manner, thus indicating that interaction
with S100B may play a role in the regulation of cellular cal-
cium homeostasis (Gentil et al, 2001). Ahnak/Desmoyokin is
expressed in the extra-embryonic membranes during gas-
trulation, but accumulates in the heart, neural crest, and its
derivatives during organogenesis. This expression pattern
during development is shared by several developmentally
important gene products, including AP2.2, Hox-7, dHAND,
eHAND, and twist (Kingsley et al, 2001). Results of further
analysis of Ahnak/Desmoyokin expression in mouse con-
ceptuses have suggested that Ahnak/Desmoyokin may also
be involved in tissue organization during mouse develop-
ment (Downs et al, 2002).
In human epidermis, Ahnak/Desmoyokin is localized
mainly along the cell boundary, which implies some func-
tional involvement in cell adhesion (Hieda and Tsukita,
1989). On the other hand, Ahnak/Desmoyokin is localized in
Abbreviations: DMBA, 7,12-dimethylbenz(a)anthracene; pAb, po-
lyclonal antibody; PBS, phosphate-buffered saline; RA, retinoic
acid; TPA, 12-o-tetradecanoylphorbol-13-acetate
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the nucleus in non-epithelial cells (Shtivelman and Bishop,
1993). Recently, it has been found that Ahnak/Desmoyokin
shuttles between nucleus and cytoplasm/plasma mem-
brane, and that its translocation depends on extracellular
calcium concentration (Hashimoto et al, 1995; Nie et al,
2000), as well as on phosphorylation by PKB, which is ac-
tivated by cell–cell contact inducing differentiation in cul-
tured epidermal cells (Sussman et al, 2001). More recent
study of expression analysis in adult mouse tissue found
that Ahnak/Desmoyokin is preferentially expressed in all
muscular and epithelial cells of lining epithelium, but is ab-
sent from epithelium with secretory or absorptive functions
(Gentil et al, 2003).
These experimental investigations of the functional roles
of Ahnak/Desmoyokin were mainly based on analyses using
antibodies and expression vectors. Although these studies
do suggest possible functions of Ahnak/Desmoyokin, its
precise biological function could be more directly investi-
gated with the ‘‘loss of function’’ analysis used in our study
of Ahnak/Desmoyokin-deficient ES cells and mice.
Results
Generation of Ahnak/Desmoyokin-deﬁcient ES cells and
their proliferation and differentiation in vitro For an in-
vestigation of the functions of Ahnak/Desmoyokin by means
of ‘‘loss of function’’ analysis, Ahnak/Desmoyokin-deficient
ES cells were generated. To design the targeting construct,
we cloned 129 mouse genomic DNA of Ahnak/Desmoyokin
and constructed a replacement targeting vector that was
expected to delete approximately 3.2 kb of genomic DNA
encoding the ATG start codon, the N-terminal domain, and
the head portion of the repeat domain of Ahnak/Desmoyo-
kin (Fig 1A). The Ahnak/Desmoyokin targeting construct was
electroporated into ES cells and selected for resistance to
G418. We obtained seven independent ES clones that were
found to accurately target the Ahnak/Desmoyokin genomic
locus. Ahnak/Desmoyokin-deficient ES cells were then gen-
erated by a second targeting to neo-deleted heterozygous
ES cells, which was confirmed by Southern blot analysis
(Fig 1B). To analyze the proliferation of mutant ES cells, we
evaluated the doubling time as described in Materials and
Methods. There was no difference between wild-type and
mutant ES cells, and both doubling times calculated were
10 h. To examine the differentiation of Ahnak/Desmoyo-
kin-deficient ES cells, we used retinoic acid (RA) treatment
to generate embryoid bodies. The morphology of these
embryoid bodies showed no difference between wild-type
and mutant ES cells, and both genotypes showed rhythmi-
cal contraction reflecting differentiation into cardiac muscle
cells (Fig 2A, upper panel). We also induced neural differ-
entiation of mutant ES cells by cultivating them on PA6
feeder cells (Kawasaki et al, 2000). Co-culture of mutant ES
cells on PA6 feeder cells produced morphologically distinct
neural differentiation similar to that of wild-type ES cells (Fig
2A, lower panel ). Furthermore, the embryoid bodies gener-
ated from both wild-type and mutant ES cells expressed
the differentiation marker proteins of cardiac myocytes (sa-
rcomeric a-actinin) (Takahashi et al, 2003) and neuroepi-
thelial precursor cells (nestin) (Jin et al, 2002) (Fig 2B). These
results indicate that Ahnak/Desmoyokin-deficient ES cells
still have the developmental potential to differentiate into
several lineages including cardiac cells and neural cells.
In summary, proliferation and differentiation of Ahnak/
Desmoyokin-deficient cells were not affected in vitro.
Generation of Ahnak/Desmoyokin-deﬁcient mice Ahnak/
Desmoyokin-deficient mice were generated for in vivo func-
tional analysis. Two targeted heterozygous ES clones were
micro-injected into host BDF1xBDF1 blastocysts. Southern
blot analysis of genomic DNA extracted from the tails of the
mice demonstrated that crosses of heterozygous mutant
mice yielded offspring of all three possible genotypes at the
Mendelian ratio (Fig 1C, data not shown). An immunopre-
cipitation assay was used to detect Ahnak/Desmoyokin
expression. An immunoprecipitation assay using the poly-
clonal antibody for the middle portion of AHNAK/desmoyo-
kin (M-DY pAb) showed that the Ahnak/Desmoyokin protein
was specifically immunoprecipitated from epidermal cell
lysates of wild-type mice, but not from those of mutant mice
(Fig 1D). To exclude the possibility of unwanted expression
due to read-through of the downstream region, we devel-
oped a new polyclonal antibody against the C-terminal
portion of Ahnak/Desmoyokin (C-DY pAb), for use in an
immunoprecipitation assay, which demonstrated that no
protein could be immunoprecipitated from epidermal cell
lysates of mutant mice with C-DY pAb (Fig 1D). Western
blot analysis of whole tissue extracts from skin, and
immunohistochemical analysis of skin sections with C-DY
pAb also verified that no protein was expressed in mutant
mice (Fig 1E, Fig 4, top panel). These findings proved that
the generation of Ahnak/Desmoyokin null mutant mice was
successful.
Although Ahnak/Desmoyokin is supposed to play a role
in mouse development, Ahnak/Desmoyokin-deficient mice
showed no developmental defects or macroscopic abnor-
malities. These findings, together with those obtained with
the in vitro experiments, lead us to conclude that Ahnak/
Desmoyokin deficiency has no effect on mouse develop-
ment.
Analysis of epidermis from Ahnak/Desmoyokin-deﬁ-
cient mice To evaluate the effect of Ahnak/Desmoyokin
deficiency on cell proliferation and differentiation in vivo, the
skin of mutant mice was histologically analyzed. Skin sec-
tions from mutant mice at different ages during appendage
development showed no abnormalities of hair follicles and
sebaceous glands, suggesting that the skin appendage de-
velopment of mutant mice was not affected (Fig 3A). As
translocation of Ahnak/Desmoyokin to the plasma mem-
brane is induced by PKC activation with 12-o-tetrad-
ecanoylphorbol-13-acetate (TPA) (Hashimoto et al, 1995),
we examined the effect of TPA stimulation on Ahnak/Des-
moyokin-deficient epidermal cells. Both wild-type and
mutant mice treated with TPA and BrdU showed similar
increase in epidermal thickness and number of BrdU-labe-
led cells (Fig 3B, bottom panel, Table I), indicating that pro-
liferation of Ahnak/Desmoyokin-deficient epidermal cells
were not affected in vivo. In the immunohistochemical anal-
ysis of the skin sections, mutant epidermal cells expressed
the epidermal differentiation markers keratin 1, keratin 5,
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Figure 1
Targeted disruption of the Ahnak/Desmoyokin gene. (A) Structure of the Ahnak/Desmoyokin genomic locus and the targeting construct. The
targeting vector was used to delete approximately 3.2 kb of genomic DNA, including the ATG start codon of Ahnak/Desmoyokin. N, the region
encoding the N-terminal domain of 251 amino acids; repeated domain, the region encoding a repeating unit of 4392 amino acids; C, the region
encoding C-terminal 1000 amino acids; 50, 50 untranslated region; 30, 30 untranslated region; neo, neomycin resistance gene; DT, diphtheria toxin
gene; H, HindIII; E, EcoRI. Triangles flanking neo indicate loxP sites. The zigzag line connected to the 50 homologous region of the targeting vector
represents the pBluescript vector backbone. Black boxes represent the 0.5-kb EcoRI fragment as a 50probe and the 1.2-kb KpnI–EcoRV fragment
as a 30 probe for Southern blot analysis. Arrows indicate primers for PCR genotyping (for primers A, B, and C, see Materials and Methods). (B, C)
Southern blot analysis. Genomic DNA from ES cells (B) and tail (C) were prepared. The genomic DNA digested with HindIII or EcoRI were
electrophoresed, transferred to a nylon membrane, and hybridized with a 50 or a 30 probe. Homologous recombination at the 50 portion was
confirmed by detection of the wild-type allele as a 9.6-kb HindIII fragment, the targeted allele as 7.6-kb HindIII fragment, and the neo-deleted locus
as a 13.4-kb HindIII fragment. Homologous recombination at the 30 portion was confirmed by detection of the wild-type allele as a 25.4-kb EcoRI
fragment, and of the targeted and neo-deleted allele as a 19.3-kb EcoRI fragment (data not shown). Symbols: þ /þ , wild-type; /, homozygote;
þ /, heterozygote; del/þ , neo-deleted heterozygous ES cells; del/, second targeted ES cells. (D) Immunoprecipitation of Ahnak/Desmoyokin
protein. Keratinocytes of wild-type and mutant mice were labeled with [35S]methionine and protein extracts were analyzed by immunoprecipitation
with the polyclonal antibodies against the middle portion of Ahnak/Desmoyokin (M), the C terminal portion of Ahnak/Desmoyokin (C), and STAT3 as a
control (STAT3). Asterisk denotes non-specific bands that is also seen in immunoprecipitation with control normal rabbit serum. The signal of these
bands did not change with increased protein volume loading, whereas the signal of 700 kDa (Ahnak/Desmoyokin) band was enhanced with
increasing protein volume. (E) Western blot analysis of whole tissue extract from skin of mutant mice with C-DY pAb.
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involucrine, and laminin 5 in the appropriate locations (Fig
4), demonstrating that Ahnak/Desmoyokin-deficient epider-
mal cells showed normal differentiation.
Ahnak/Desmoyokin was first isolated from bovine muzzle
epidermis as a desmosome-related protein (Hieda and Tsu-
kita, 1989), and thought to be involved in epidermal cell
adhesion. To test this assumption, we examined the epi-
dermal intercellular junctions of Ahnak/Desmoyokin-
deficient mice. For detailed analysis of the ultrastructure
of intercellular junctions, we utilized immunoelectron micro-
scopy. Ahnak/Desmoyokin localized at the periphery of des-
mosomal plaque in wild-type mice, but there was no protein
expression of Ahnak/Desmoyokin in mutant mice. However,
the ultrastructure of the intercellular junctions of mutant
mice was indistinguishable from that of wild-type animals.
Furthermore, localization of Desmocollin, the major con-
stituent of desmosome, was not affected (Fig 5). These
findings clearly indicated that Ahnak/Desmoyokin is not
functionally associated with epidermal desmosomes nor
implicated in epidermal cell adhesion.
Tumorigenesis of Ahnak/Desmoyokin-deﬁcient mice Al-
though no spontaneous tumor formation was observed in
mutant mice up to 2 y of age (data not shown), the findings
of previous studies demonstrating downregulation in
malignant tumor cell lines (Shtivelman et al, 1992) and
tumorigenic HRAS-transformed rodent cells (Zuber et al,
2000) prompted us to examine whether Ahnak/Desmoyokin
deficiency affects susceptibility to carcinogen application.
To this end, we performed two-stage carcinogenesis ex-
periments with an initiator, 7,12-dimethylbenz(a)anthracene
(DMBA), plus a tumor promotor, TPA on the skin of wild-type
and mutant mice. DMBA introduces a point mutation in co-
don 61 (A182 to T) of the c-Ha-ras gene, and application of
TPA after initiation with DMBA leads to the appearance of
papillomas, some of which can progress to malignant car-
cinomas (Quintanilla et al, 1986; Finch et al, 1996). Since our
results showed no significant difference in tumor formation
rates between wild-type and mutant mice (Fig 6), and no
malignant tumors were observed in this experiment, we
concluded that Ahnak/Desmoyokin deficiency has no or
minimal effect on tumorigenesis, and that Ahnak/Desmoyo-
kin may not be implicated in malignant cell transformation
in vivo.
Discussion
In this study, we evaluated the possible roles for Ahnak/
Desmoyokin suggested in previous studies, by means of
‘‘loss of function’’ analysis, which enabled us to investigate
more directly its precise biological function. Viability and
fertility of mutant mice clearly indicated that Ahnak/Des-
moyokin is not a critical gene for mouse development, un-
like what could be expected from its expression pattern in
developmental stages.
Figure 2
Differentiation of mutant ES cells. (A)
Embryoid body formation (top panel) and
neural differentiation (bottom panel) of
wild-type ES cells (þ /þ ), neo-deleted
heterozygous ES cells (del/þ ), and Ah-
nak/Desmoyokin-deficient ES cells (del/).
(B) Expression of the differentiation marker
proteins of cardiac myocytes (a-actinin)
and neurons (nestin) in the embryoid bod-
ies generated from ES cells. Scale bar,
100 mm.
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Ahnak/Desmoyokin was first isolated from bovine muzzle
epidermis as an epidermal desmosome-related protein, and
therefore was named Desmoyokin (Hieda and Tsukita,
1989). Later studies found that Ahnak/Desmoyokin local-
ized substantially in the non-desmosomal areas of the cell
membrane of human keratinocytes with slight accumulation
around desmosomes (Masunaga et al, 1995), thus suggest-
ing its functional role in cell adhesion not directly associated
with, but stabilizing epidermal desmosomes. However,
analysis of its localization could not fully address the ques-
tion as to whether Ahnak/Desmoyokin is in fact related to
epidermal cell adhesion. Phenotypic analysis of skin sec-
tions from mutant mice provided conclusive evidence that
Ahnak/Desmoyokin is neither involved in stabilization of
epidermal desmosomes nor related to epidermal cell ad-
hesion.
Recently, Ahnak/Desmoyokin was found to be localized
within small cytoplasmic vesicles called enlargosomes,
which are thought to be a new type of vesicle capable
of rapid, calcium-dependent exocytosis (Borgonovo et al,
2002). Fusion of these vesicles induces redistribution of
Ahnak/Desmoyokin to the external cell surface and en-
largement of the plasma membrane. Enlargosomes have
Figure 3
Histological analysis of skin section from wild-type (þ /þ ) and
mutant (/) mice. (A) Histological analysis of the skin sections from
mice at postnatal day 3 (PND 3), 2 wk (2W), and 4 wk (4W). (B) TPA
treatment caused mild epidermal hyperplasia and increased BrdU-
labeled basal cells in both genotypes. Arrows denote BrdU-labeled
basal cells. Scale bar, 100 mm.
Table I. Labeling index of 12-o-tetradecanoylphorbol-13-ace-
tate (TPA)-treated or untreated adult epidermis
AHNAK/Desmoyokin genotype
þ /þ þ / /
TPA 20.0 (3) 20.6 (3) 21.6 (3)
No treatment 2.7 (3) 2.2 (3) 2.4 (3)
Wild-type (þ /þ ), heterozygous (þ /), and mutant (/) mice were
treated with TPA or acetone vehicle. The average numbers of BrdU-
labeled cells/100 basal cells with observation of 3000 basal cells were
shown. Number in parentheses indicates number of mice analyzed.
Figure4
Immunohistochemical analysis of skin sections. Immunostaining of
skin sections from wild-type (þ /þ ) and mutant (/) mice with pri-
mary antibodies against C-terminal portion of Ahnak/Desmoyokin (C-
DY), K1, K5, Involucrine, and Laminin 5. White dashed line indicates
basement membrane zone. Scale bar, 100 mm.
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been proposed to participate in cell membrane differenti-
ation and repair (Borgonovo et al, 2002). This finding,
together with that of its regulated expression and
phosphorylation in a cell-cycle-dependent manner (Shtivel-
man and Bishop, 1993), led us to speculate that Ahnak/
Desmoyokin deficiency might affect cell proliferation and
differentiation. However, our ‘‘loss of function’’ analysis
conducted with mutant ES cells and epidermal cells left us
no choice but to conclude that Ahnak/Desmoyokin by itself
is unlikely to play a crucial role in cellular proliferation and
differentiation.
Susceptibility of mice in two-stage carcinogenesis pro-
tocol is influenced by genetic background. For example,
C57BL/6 mice are resistant, whereas 129 mice are sensitive
to TPA promotion in the protocol (Reiners Jr and Singh,
1997; Guo et al, 1999). In our experiments, we obtained the
mutant mice by mating of the chimeric mice generated from
R1-ES cells (129 strain) with C57BL/6 mice. Therefore, the
genetic background of the mutant mice is the mixture of 129
and C57BL/6. Although, our tumor studies could be affect-
ed by genetic resistance, the comparison among littermates
allowed us to conclude that Ahnak/Desmoyokin deficiency
has only a minimal effect on tumorigenesis and malignant
cell transformation in vivo.
Recently, Baudier’s group reported their results of a ‘‘loss
of function’’ analysis of Ahnak/Desmoyokin using downreg-
ulation with a small interfering RNA, and proposed that
Ahnak/Desmoyokin might fulfill a function in regulating cor-
tical actin cytoskeleton organization and cell membrane
cytoarchitecture. They found that downregulation of Ahnak/
Desmoyokin in MDCK cells using specific siRNA prevented
cortical actin cytoskeleton from reorganizing, which in turn
resulted in reduced cell height (Benaud et al, 2004). How-
ever, in our study Ahnak/Desmoyokin-deficient epidermal
cells appeared morphologically normal in vivo. There may
be two possible explanations for these discrepant obser-
vations. One is that siRNA designed against central repeat-
ed elements of Ahnak/Desmoyokin may have impaired
unknown proteins containing similar sequences, such as
titin, which has a PEVK region similar to the central repeated
sequence of Ahnak/Desmoyokin (Wernyj et al, 2001). The
other explanation is that acute loss of Ahnak/Desmoyokin
caused by siRNA might be phenotypically different from its
constitutive elimination resulting from the knockout proce-
dure. For example, acute loss of Rb caused by the Cre-loxP
system and germline loss of the Rb function showed dif-
ferent phenotypes in cell-cycle regulation, and this differ-
ence can be supposed to have been caused by functional
compensation due to the prolonged absence of Rb in germ
line mutation (Sage et al, 2003). This notion raises the pos-
sibility of the existence of compensating proteins function-
ally related to Ahnak/Desmoyokin. The mutant mice and ES
cells generated for our study can be expected to become
useful tools for the further investigation of existence of
compensating and redundantly contributing proteins. Al-
though Ahnak/Desmoyokin may yet have important func-
tions as previously reported, we were able to demonstrate
that its functional mechanism is not so simple as to show
overt phenotypes following the knockout procedure. In that
respect, our study is thought to have made a major con-
tribution towards the full clarification of the true functions of
Ahnak/Desmoyokin in living organisms.
Materials and Methods
Isolation of the Ahnak/Desmoyokin gene and construction of
the targeting vector The Ahnak/Desmoyokin genomic DNA was
Figure 5
Immunoelectron microscopic examination of epidermal intercellu-
lar junctions. The epidermis of wild-type (þ /þ ) and mutant (/)
mice was stained with polyclonal antibodies against the middle portion
of Ahnak/Desmoyokin (M-DY), the C-terminal portion of Ahnak/Des-
moyokin (C-DY), and Desmocollin (Desmocollin). The large 10 nm gold
particles indicate localization of Ahnak/Desmoyokin (top and middle
panels). The small 5 nm gold particles indicate localization of Des-
mocollin (bottom panel). Scale bar, 200 nm.
Figure 6
Two-stage chemical skin carcinogenesis experiments. Percentages
of tumor-free mice during the 20-wk duration of the experiment. Only
one or two tumors were observed in tumor-bearing mice of each gen-
otype. There were no major differences in tumor formation rates among
wild-type (þ /þ , black bars), heterozygous (þ /, gray bars), and mu-
tant (/, white bars) mice. The actual numbers of tumor-free mice of
each genotype and time point were denoted on the bars.
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obtained from a 129/SvJ mouse lambda genomic library (Strata-
gene, La Jolla, California). A 1.3-kb blunted EcoRI–NotI fragment of
the negative selection marker DT-A, containing the diphteria toxin
A-fragment from pMC1DTpA, was inserted into blunted BamHI–
NotI sites of pBluescript II KS (þ ) vector (pBS) (Stratagene), re-
sulting in pBS-DT. A 6.5-kb blunted HindIII-blunted SalI fragment
(SalI from the Lambda FIX II vector) of genomic DNA was inserted
into the SmaI site of pBS-DT, resulting in pankL-DT. A 1.7-kb
EcoRI-blunted NotI fragment containing PGK-Neo flanked by two
loxP sites was inserted into the EcoRI-blunted HindIII sites of pBS,
resulting in pBS-Neo. A 1.7-kb EcoRI–SalI fragment from pBS-Neo
was inserted into the EcoRI–SalI sites of pankL-DT, and a 2.7-kb of
blunted EcoRI–SmaI fragment of genomic DNA containing 50 non-
coding region of Ahnak/Desmoyokin into the blunted KpnI–SmaI
sites of pBS, resulting in pBS-S. Finally, a 9.5-kb blunted SalI–NotI
fragment of pankL-DT was inserted into the SmaI–NotI sites of
pBS-S, resulting in a 15.1-kb targeting vector. Prior to its elect-
roporation into embryonic stem cells, the targeting vector was lin-
earized with NotI site at the 30 end of the DT-A cassette.
Generation of mutant ES cells and mice 3  107 R1-ES cells
were electroporated with 75 mg of the linearized targeting construct
(0.4 cm cuvette, 240 V, 500 mF) and then plated onto feeder cells.
After 7 d selection with 150 mg per mL of G418, resistant colonies
were harvested. Each colony harvested was divided for culture and
PCR screening. Positive clones were expanded and confirmed by
Southern blot analysis.
For the second targeting, targeted ES cells were transiently
transfected with expression plasmid encoding Cre recombinase.
After Cre-mediated recombination, neo-deleted ES clones were
electroporated with the same targeting vector as used for the first
targeting. Subsequently, G418 selection and PCR screening were
processed in the same manner as for the first targeting.
To generate Ahnak/Desmoyokin-deficient mice, monoallelically
targeted ES clones with a normal karyotype were injected into
BDF1xBDF1 blastocysts. PCR genotyping was performed with one
forward primer, which is specific for the genomic sequence present
in both the wild-type and targeted allele (primer A, 50-GGGCA-
GGTTTCCCCCTTTCTGTCTTTATTG-30), and two reverse primers.
One of these is specific for the neo-cassette poly-A addition signal
sequence present in the targeted allele (primer B, 50-CGCATCGCC-
TTCTATCGCCTTCTTGACGAG-30), and the other for the sequence
present in the wild-type allele disrupted by gene targeting (primer
C, 50-GGCCTTCCACAGTCATTTGGTCATTTCTGC-30). Primer pairs
A and B yielded a 400-bp fragment from the mutant alleles, which
was then digested with the SpeI producing 300- and 100-bp frag-
ments. Primer pairs A and C yielded a 400-bp fragment from the
wild-type allele, which was the same size as the mutant but not
digested by SpeI. PCR screening as described above could dis-
criminate among wild-type, heterozygous, and homozygous mice.
Southern blot analysis The 0.5-kb EcoRI fragment and the 1.2-
kb KpnI–EcoRV fragment, located, respectively, upstream and
downstream of the homologous region of the targeting vector, were
used as probes. Genomic DNA of mutant ES cells and mutant mice
was purified and digested with either HindIII or EcoRI, fractionated
on a 0.7% agarose gel, transferred to a nylon membrane (Amer-
sham, Buckinghamshire, UK), and hybridized with a 32P-labeled
probe.
Preparation of antibody Preparation of the polyclonal antibody
for the middle portion of Ahnak/Desmoyokin (designated M-DY
pAb in this study) was previously described (Hashimoto et al,
1993).
To obtain the polyclonal antibody, which specifically recognizes
the C-terminal portion of Ahnak/Desmoyokin (designated C-DY
pAb), a 300-bp genomic DNA fragment, which encodes from
threonine 5419 to glysine 5519 of Ahnak/Desmoyokin, was sub-
cloned in-frame into expression vector pGEX-5X-3 (Amersham).
The glutathione-S-transferase (GST)-fusion protein was produced
and purified with a glutathione–sepharose 4B column (Amersham)
for immunization of rabbits. The obtained anti-Ahnak/Desmoyokin
serum was further purified with a glutathione–sepharose column,
to which GST was bound, for exclusion of the anti-GST antibody.
Immunoprecipitation and western blotting 2  106 epidermal
cells obtained from newborn mice were labeled in methionine-free
medium containing 250 mCi [35S]methionine per mL for 1h. The
labeled cells were solubilized in 500 mL of RIPA buffer (10 mM Tris,
pH 7.5, 1% NP40, 0.1% sodium deoxycholate, 0.1% SDS, 150 mM
NaCl, 1 mM EDTA) containing 10 mg per mL of protease inhibitor
(complete EDTA free; Roche Diagnostics, Mannheim, Germany).
The protein G–sepharose beads coupled with each anti-serum (M-
DY pAb, C-DY pAb, and normal rabbit serum) were mixed with 80
mL of the supernatants of the labeled cell lysates and incubated
overnight at 41C. The sepharose beads were washed with RIPA
buffer and the immunoprecipitated proteins were analyzed by
means of 5% SDS-polyacrylamide gel electrophoresis and auto-
radiography.
The lysates (20 mg of protein) from frozen tissue specimens of
the skin were separated on a 5% SDS-polyacrylamide gel and
transferred to polyvinylidene difluoride membrane (Millipore, Bill-
erica, Massachusetts) for 2 h at 300 mA. The transfers were sub-
sequently incubated with C-DY pAb (1:200 dilution) overnight at
41C. Immunoreactive protein bands were visualized by the ECL
reaction kit (Amersham).
In vitro differentiation of mutant ES cells Embryoid body for-
mation from ES cells was performed as described previously
(Gajovic et al, 1998). During the first 4 d, 400 ES cells were cultured
in suspension for embryoid body preparation with or without 1 mM
all trans-RA (Sigma, St Louis, Missouri), and transferred to gelatin-
coated cell culture dishes with medium lacking RA, and further
cultured for 5 d.
For neural differentiation, stromal cell-derived inducing activity-
induced neurogenesis of ES cells was performed as described
previously (Kawasaki et al, 2000). In this procedure, ES cells were
plated on fixed PA6 cells at a density of 2  104 cells per 35 mm
culture dish and cultured for 10 d.
Immunoﬂuorescence After fixation with 4% paraformaldehyde in
0.1 M phosphate-buffered saline (PBS), pH 7.4, for 15 min, cells
were treated with 0.1% Triton X-100 (Nacalai, Kyoto, Japan) in 0.1
M PBS for 15 min. After BSA block (5% BSA in PBS), cells were
incubated with primary antibodies at 41C overnight. Five microm-
eter cryosections of the skin obtained from newborn mice were
fixed with cold acetone and blocked in 10% goat serum in PBS
with 0.1% Tween-20 for 30 min. Fixed sections were incubated
with primary antibodies at 41C overnight. The following primary
antibodies were used: mouse anti-a-actinin (sarcomeric) (1:600
dilution) (Sigma), mouse anti-nestin (1:400 dilution) (BD Bioscienc-
es Pharmingen, San Diego, California), rabbit anti-K1, K5, in-
volucrine (1:200 dilution) (BabCO, Richmond, California), laminin 5
(GB3, gift of professor Ortonne) (1:100 dilution), C-DY pAb (1:100
dilution). Fluorescence labeling was performed with Alexa Fruor
488-conjugated anti-mouse IgG antibody (Molecular Probes, Eu-
gene, Oregon) (1:1000 dilution), or FITC-conjugated anti-rabbit IgG
antibody (Cappel, Aurora, Ohio) (1:500 dilution). The fluorescence
signals were detected with Olympus IX70 microscope (Olympus,
Nagano, Japan).
Proliferation assay of mutant ES cells and epidermal cells The
log-phase ES cells were plated at a density of 2  105 cells per
well on 24-well plates, and counted every 4 h for three times in-
dependently. These counts were plotted as cells per mL (  105)
against time (h). The average doubling time to the log phase of the
growth curves were calculated.
For BrdU-labeling assay, Ahnak/Desmoyokinþ /þ (n¼ 6), Ahnak/
Desmoyokinþ / (n¼ 6), and Ahnak/Desmoyokin/ (n¼ 6) mice
were shaved at 6 wk of age. Two days later, the mice were topically
treated with 2.5 mg of TPA in 100 mL of acetone or the acetone
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vehicle twice a week for 2 wk (four doses total). Forty-eight hours
after the last treatment, the mice received intraperitoneal injection
of BrdU (100 mg per g body weight) in PBS. Thirty minutes later, the
mice were euthanized and the paraffin-embedded skin sections
were prepared. BrdU staining of the skin sections were performed
with rat monoclonal anti-BrdU (Oxford Biotechnology, Oxford, UK)
and biotinylated rabbit anti-rat IgG (DAKO, Carpinteria, California).
Labeled nuclei were counted for each genotype and treatment.
Immunoelectron microscopy Post-embedding immunogold
electron microscopy was performed as previously described (Is-
hida-Yamamoto et al, 1996). Briefly, mouse skin tissue was cryo-
protected with 15% glycerol-PBS, rapidly cryofixed with liquid
propane at 1901C, subjected to cryosubstitution in methanol at
801C, and embedded in Lowicryl K11M according to the man-
ufacturer’s protocol (Chemische Werke Lowi, Waldkraiburg, Ger-
many). Ultrathin sections were transferred to formvar-coated nickel
grids and incubated with M-DY pAb (1:600 dilution), C-DY pAb
(1:300 dilution), and mouse monoclonal anti-desmocollin 2, 3 an-
tibody (Parrish et al, 1990) (1:100 dilution) for 1 h at 371C. This was
followed by incubation with 10 or 5 nm gold-conjugated goat anti-
rabbit IgG (Amersham) (1:10 dilution) for 1 h at 371C. The sections
were stained with uranyl acetate and examined with a JEM-
2000EX electron microscope (JEOL, Tokyo, Japan).
Two-stage chemical skin carcinogenesis experiments For
chemical carcinogenesis studies, Ahnak/Desmoyokinþ /þ (n¼ 5),
Ahnak/Desmoyokinþ / (n¼ 8), and Ahnak/Desmoyokin/ (n¼ 8)
mice were shaved at 7–9 wk of age. Two days later, 100 mg of
DMBA in 200 mL of acetone was applied to the dorsal skin of the
mice. From 1 wk after DMBA application, a twice per week ap-
plication of 2.5 mg of TPA in 100 mL of acetone was continued for
the next 20 wk, and the mice were checked for skin tumors every
week. At the end of 20 wk, the mice were euthanized and their skin
sections processed for histology. All animal studies have been
approved by the institutional review board.
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